Lidds Q2: Moving forward - Redeye

Redeye comments on LIDDS Q2’22 report. The company advances its projects, in particular with regard to nanodotax and nanoimod. The collaboration with Johnson & Johnson has moved into the next phase and LIDDS’ leading project Liproca Depot is currently being prepared for a clinical Phase III trial. We will return with a research update, where we will review our financial forecasts and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/853580/lidds-q2-moving-forward?utm_source=finwire&utm_medium=RSS